Preserved Pharmacological Activity of Hepatocytes-Treated Extracts of Valerian and St. John's Wort

Abstract

The two herbal extracts valerian (Valeriana officinalis L.) and St. John’s wort (Hypericum perforatum L.) were studied for their metabolic changes upon incubation with freshly prepared rat hepatocytes and subsequently analysed phytochemically as well as pharmacologically in vitro. Quantitative HPLC analysis of valerian extracts revealed considerable metabolic activities with regard to sesquiterpenes and iridoids. The amount of acetoxyvalerenic acid decreased 9-fold, while that of hydroxyvalerenic acid correspondingly increased 9-fold due to O-deacetylation. The valepotriates didrovaltrate, isovaltrate and valtrate decreased 2-, 18- and 16-fold, respectively. However, the binding affinities of the incubated extracts to the benzodiazepine and picrotoxin binding site of the GABA_A receptor were quite similar to those of the non-incubated extracts. Neither valerenic acids nor valepotriates exhibited any significant effect on the two binding sites when tested as single compounds. Therefore, either other constituents represent the active ones or multiple compounds are necessary for the observed inhibitory and allosteric effects at the GABA_A receptor. Extracts of St. John’s wort were less potently metabolised than valerian. The amount of pseudohypericin and the main flavonoids (hyperoside, rutin, isoquercitrin, quercitrin, quercetin and I3,II8-biapigenin) slightly decreased during the 4-h incubation period. Both the antagonist effect at the corticotropin-releasing factor (CRF) type 1 receptor and the binding inhibition at the 5-HT transporter were attenuated during the metabolic treatment. The reduced antagonist effect correlates with the decreasing amount of pseudohypericin known to be a CRF₁ receptor antagonist. In conclusion, the incubation of plant extracts with freshly prepared rat hepatocytes represents a useful approach to study the pharmacological action of metabolised plant extracts. The consistent pharmacological activity of both valerian and St. John’s wort is concordant with the known clinical efficacy of pharmacological activities.

In vitro metabolism - rat hepatocytes - Valeriana officinalis L. - Hypericum perforatum L. - receptor binding - CRF (corticotropin-releasing factor) antagonism

References

• 1 Hadley S, Petry J J. Valerian.  Am Fam Physician. 2003;  67 1755-8
• 2 Houghton P J. The scientific basis for the reputed activity of Valerian.  J Pharm Pharmacol. 1999;  51 505-12
• 3 Cavadas C, Araujo I, Cotrim M D, Amaral T, Cunha A P, Macedo T. et al . In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABA_A receptor in rat brain.  Drug Res. 1995;  45 753-5
• 4 Lapke C, Schilcher H, Riedel E. Free amino acids in commercial preparations of Valeriana officinalis L.  Pharm Pharmacol Lett. 1997;  7 172-4
• 5 Karobath M, Sperk G. Stimulation of benzodiazepine receptor binding by γ-aminobutyric acid.  Proc Natl Acad Sci USA. 1979;  76 1004-6
• 6 Moore L B, Goodwin B, Jones S A, Wisely G B, Serabjit-Singh C J, Willson T M. et al . St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.  Proc Natl Acad Sci USA. 2000;  97 7500-2
• 7 Kientsch U, Bürgi S, Ruedeberg C, Probst S, Honegger U E. St. John’s wort extract Ze 117 (Hypericum perforatum) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces β-adrenoceptor numbers on cultured rat brain cells.  Pharmacopsychiatry. 2001;  34 (Suppl 1) 56-60
• 8 Butterweck V. Mechanism of action of St John's wort in depression: what is known?.  CNS Drugs. 2003;  17 539-62
• 9 Chen F, Rezvani A H, Lawrence A J. Autoradiographic quantification of neurochemical markers of serotonin, dopamine and opioid systems in rat brain mesolimbic regions following chronic St John's wort treatment.  Naunyn Schmiedebergs Arch Pharmacol. 2003;  367 126-33
• 10 Bissette G, Klimek V, Pan J, Stockmaier C, Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects.  Neuropsychopharmacology. 2003;  28 1328-35
• 11 Franklin M, Reed A, Murck H. Sub-chronic treatment with an extract of Hypericum perforatum (St. John’s wort) significantly reduces cortisol and corticosterone in the rat brain.  Eur Neuropsychopharmacol. 2004;  14 7-10
• 12 Simmen U, Bobirnac I, Ullmer C, Lubbert H, Berger Buter K, Schaffner W. et al . Antagonist effect of pseudohypericin at CRF1 receptors.  Eur J Pharmacol. 2003;  458 251-6
• 13 Béïque J -C, Lavoie N, de Montigny C, Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.  Eur J Pharmacol. 1998;  349 129-132
• 14 De Graaf I AM, Van Meijeren C E, Pektas F, Koster H J. Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism.  Drug Metab Dispos. 2002;  30 1129-36
• 15 Berry M N. High-yield preparation of morphologically intact isolated parenchymal cells from rat liver.  Methods Enzymol. 1974;  32 625-32
• 16 McQueen C A. Isolation and culture of hepatocytes from different laboratory species. In: Tyson CA, Frazier JM, editors Methods in Toxicology. New York; Academic Press 1993: pp 255-70
• 17 Sigel E, Buhr A. The benzodiazepine binding site of GABA_A receptors.  Trends Pharmacol Sci. 1997;  18 425-9
• 18 Ortiz J G, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [³ H]flunitrazepam binding, synaptosomal [³ H]GABA uptake, and hippocampal [³ H]GABA release.  Neurochem Res. 1999;  24 1373-8
• 19 Bos R, Hendriks H, Scheffer J JC, Woerdenbag H J. Cytotoxic potential of valerian constituents and valerian tinctures.  Phytomedicine. 1998;  5 219-25
• 20 Gobbi M, Valle F D, Ciapparelli C, Diomede L, Morazzoni P, Verotta L. et al . Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex.  Naunyn Schmiedebergs Arch Pharmacol. 1999;  360 262-9